0001562180-23-005819.txt : 20230707
0001562180-23-005819.hdr.sgml : 20230707
20230707160828
ACCESSION NUMBER: 0001562180-23-005819
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230705
FILED AS OF DATE: 20230707
DATE AS OF CHANGE: 20230707
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perry Andrew
CENTRAL INDEX KEY: 0001877793
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 231076875
MAIL ADDRESS:
STREET 1: C/O G1 THERAPEUTICS, INC.
STREET 2: 700 PARK OFFICES DRIVE, SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0407
4
2023-07-05
false
0001560241
G1 Therapeutics, Inc.
GTHX
0001877793
Perry Andrew
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
false
true
false
false
Chief Commercial Officer
true
Common Stock
2023-07-05
4
S
false
355.00
2.4537
D
55945.00
D
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. Such sales were automatic and intended to qualify under Rule 10b5-1.
The price represents the weighted average price with a low of $2.4250 and a high of $2.4704. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents (i) 1,095 shares of common stock; (ii) 3,750 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023, and (iv) 35,000 RSUs from award granted on May 10, 2023.
/s /Sandi James, attorney-in-fact
2023-07-07